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Background: As patients with juvenile idiopathic arthritis (JIA) progress into adulthood, long-term outcome is
determined by disease activity, physical and psychosocial development. Decreased aerobic capacity may play a
critical role in health-related outcomes in JIA, since it has been linked with cardiovascular morbidity and mortality in
late adulthood. The objectives of the current study are to examine the aerobic capacity and its relation to
parameters of disease activity in children, adolescents and young adults with JIA.
Methods: Sixty-three patients with JIA (aged 10–27 years) were cross sectional studied regarding their aerobic
capacity and correlations were made to demographic, disease-related variables, and medication utilization. in a
cross-sectional study group of 63 patients of all subtypes. Patients were divided in three age groups, 10–13 years;
14–17 years and 18–27 years.
Results: Reduced aerobic capacity is found in clinical remission as well as active disease in all subtypes and all age
groups. Aerobic capacity is more impaired in active disease shown by DAS 28, JADAS 27, ESR and serum thrombocyte
counts. Lower haemoglobin has a negative impact. Long-term used medication including methotrexate and
corticosteroids didn’t influence outcome. There is no association with current sports participation.
Conclusion: Reduced aerobic capacity is present in children and adolescents with JIA, both in active disease and in
patients with remission. Measures of aerobic capacity may serve as important outcome measure in JIA.
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Although Juvenile Idiopathic Arthritis (JIA) is generally
thought to have a favourable outcome [1], in reality its
course may be less propitious. At adult age, persistent
disease activity and functional impairment have been
reported in more than half of the patients [2-6]. More-
over, disease related chronic inflammation may cause
protein loss and fat accumulation [7], increasing the risk
for obesity and cardiovascular disease in this population
[8]. Systemic inflammation, immune dysfunction and its
treatment [9-12], might also contribute to the increased
mortality rate in JIA [10,11].* Correspondence: n.wulffraat@umcutrecht.nl
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reproduction in any medium, provided the orIn addition to these disease-related factors [5], factors
influencing morbidity in the general population must
also be considered as they are likely to have heightened
effect on patients with JIA. For example, low aerobic
capacity, a marker of physical fitness, may play a critical
role in health-related outcomes in JIA since it has been
linked with an increased risk of developing chronic dis-
eases including cardiovascular diseases, diabetes, cancer,
hypertension, obesity, depression and osteoporosis [13],
as well as an increased risk of mortality in adults [14].
Physical fitness is a multidimensional concept defined as
a set of attributes that people possess or achieve that relate
to the ability to perform physical activity [15]. It is com-
prised of skill-related (e.g. agility, coordination), health-
related (e.g. cardiovascular capacity), and physiological
components [16]. In adults, the level of physical fitness is
a powerful predictor of mortality in both healthy andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physical fitness is the aerobic capacity, commonly defined
as the maximal or peak volume of oxygen uptake
(VO2peak) during an incremental exercise test to exhaus-
tion. VO2peak is expressed either as an absolute value in
liters of oxygen per minute (l/min) or as a relative value in
milliliters of oxygen per kilogram of bodyweight per mi-
nute (ml/kg/min). The relative value is frequently used to
compare the fitness levels of patients with a chronic dis-
ease including a wide range of ages, body sizes and disease
severity.
Aerobic capacity has been shown to be impaired in both
younger children and adolescents with JIA [19-21]. These
impairments may be associated with a combination of the
condition-related pathophysiology itself, its treatment (e.g.
medications), hypoactivity and subsequent deconditioning
[22]. Other potential contributing factors to reduced
aerobic capacity in JIA may include anemia, reduced car-
diac output, and muscular dysfunction [20].
Patients with JIA may suffer from normocytic hypochro-
mic anaemia, which implies lower oxygen transport cap-
acity of the blood, and hence, impaired oxygen transport to
the muscles. A recent study of children with JIA revealed
no significant differences in cardiac output during exercise
between the JIA group and healthy controls [23]. Muscle
atrophy, however, is a common finding in patients with JIA
that may be linked to inactivity, medication utilization (in-
cluding glucocorticoids) and disease activity [24].
Although its usage is generally related to disease activ-
ity and severity, medication itself can indirectly affect
aerobic capacity in patients with JIA through its impact
on body composition. For example, pharmacological
doses of glucocorticoids are associated with protein loss,
bone loss and insulin resistance in both hepatic and per-
ipheral tissues, leading to impaired carbohydrate metab-
olism [18,25].An inverse correlation was found between
duration of MTX treatment and respiratory muscle
function in children with systemic and polyarticular JIA,
possibly explained by a more severe disease course being
associated with long-term MTX treatment [26] In con-
trast to observed findings in adult rheumatoid arthritis
(RA) patients [27], in children with JIA, impairment of
lung function by MTX is rare[28,29]. Effects of anti-TNF
therapy on aerobic capacity are not known yet.
To our knowledge, data on aerobic capacity in relation
to the disease activity in patients with JIA are scarce
[30]. The aims of our current study are therefore to
examine the aerobic capacity and its relation to para-
meters of disease activity in children, adolescents and
young adults with JIA.
Patients and methods
All consecutive patients between 2005 and 2008 with JIA
(as classified by the International League AgainstRheumatism criteria, ILAR[31] between the ages of 10 to
27 years were asked to participate in an observational longi-
tudinal cohort study, investigating clinical parameters and
aerobic capacity in children, adolescents and young adults
with JIA over a 3-year period. A total of 63 patients pro-
vided informed consent. The results of baseline assess-
ments are described in the present study. All patients were
seen in the out-patient clinics of the paediatric or adult
departments of rheumatology & immunology at the Uni-
versity Medical Center (UMC) Utrecht. Patients were
divided into three age groups, 10–13 years, 14–17 years
and 18–27 years, with the latter patient group recruited
from the adult rheumatology department. The middle age
group (14–17 years) will be transferred to adult health care
over the course of the three-year follow-up study. The
Medical-Ethics Committee of the UMC Utrecht approved
all study procedures.
Demographic variables, disease characteristics and medi-
cation utilization (past and current) were recorded for all
patients (Table 1). Functional ability was assessed with the
validated Dutch version of the Childhood Health Assess-
ment Questionnaire [32-34]. Patients were asked about
which sports and leisure activities were performed and the
time consuming per week in a general interview [35]. Phys-
ical examination included a general assessment. Standard
laboratory values including Erythrocyte Sedimentation Rate
(ESR), C - reactive protein (CRP), thrombocytes and
haemoglobin were obtained from a blood sample collected
at the outpatient clinic. Haemoglobin counts were used to
classify anaemia based on international reference values for
in children and adolescents [36].
Aerobic capacity
Aerobic capacity (VO2peak) was assessed using a graded
cardiopulmonary exercise test (CPET) to volitional ex-
haustion performed on an electronically braked cycle
ergometer (Lode examiner, Lode BV, Groningen, the
Netherlands). The seat height was adjusted to the
patient’s comfort. Patients began cycling at a workload
of 0 Watts and this increased by 20 Watts every minute
until they were no longer able to continue cycling due to
volitional exhaustion, despite strong verbal encourage-
ment. Patients breathed through a mouthpiece, which
was connected to a calibrated metabolic cart (Oxycon
Pro, Care Fusion, Houten, the Netherlands). Expired
gases were collected and analysed for breath-by-breath
minute ventilation (Ve), oxygen uptake (VO2), carbon
dioxide exhalation (VCO2) and respiratory exchange
ratio (RER; =VCO2/VO2) using conventional equations.
The highest achieved oxygen uptake averaged over a 30-
second period was taken as VO2peak. Heart rate (HR) was
measured continuously via 3-lead ECG. To allow compari-
son of aerobic capacity with healthy controls, standardized
z-scores were determined using: Z-scores = [(observed
Table 1 Demographic and disease related variables
N = number of patients Age 10–13 yrs Age 14–17 yrs Age 18–27 yrs All patients
N = 33 N = 18 N = 12 N = 63
Boys (N) 13 6 3 22
Girls (N) 20 12 9 41
Subtype JIA N (%) 3 (9.1) 4 (22.2) 1 (8.3) 8 (12.7)
Systemic 3 (9.1) 0 (0) 0(0) 3 (4.8)
Oligo persistent 9 (27.3) 3 (16.7) 3 (25.0) 15 (23.8)
Oligo extended 3 (9.1) 2 (11.1) 2 (16.7 ) 7 (11.1)
Polyarticular RF+ 14 (42.4) 8 (44.4) 5 (41.7) 27 (42.9)
Polyarticular RF- 0 (0) 1 (5.6) 1 (8.3) 2 (3.2)
Enthesitis related Psoriatic arthritis 1 (3.0) 0 (0) 0 (0) 1 (1.6)
Disease Duration in years (IQR) 5.5 (6.0) 10.5 (6.0) 10.0 (18.0) 8.0 (7.0)
CHAQ (IQR) 1,6 (0.8) 1,4 (0.3) 1,4 (0.6)_ 1,5 (0.8)
Sports performance (hours/week, IOR) 2.0 (3.0) 3.0 (8.0) 2.5 (6.0) 2.0 (3.0)
BMI kg/m2 (IQR) 17.9 (3.3) 21.3 (4.5) 19.8 (3.9) 18.8 (4.7)
Z-score VO2peak (IQR) −0.9 (1.5) −0.8 (1.6) −0.6 (1.7) −0.8 (1.3)**
Z-score VO2peak/kg (IQR) −1.6 (1.7) −1.5 (2.1) −1.0 (2.1) −1.5 (1.9)**
ESR mm (IQR) 8.0 (10.0) 9.5 (16.0) 7.0 (14.0) 8.0 (13.0)
CRP mg/l (IQR) 2.0 (5.0) 6.0 (23.0) 6.0 (5.0) 5.5 (6.0)
Haemoglobin mmol/l (IQR) 8.0 (1.0) 7.6 (1.0) 8.7 (1.3) 7.9 (1.3)
Thrombocytes 10.9/l (IQR) 315 (102) 273 (102) 290 (93) 298 (83)
DAS28 (IQR) 1.7 (1.1) 1.8 (1.9) 1.5 (1.6) 1.6 (1.2)
JADAS 27 (IQR) 3.6 (7.1) 3.0 (22.9) 2.6 (17.1) 2.9 (9.0)
VAS patient (IQR) 0.2 (2.3) 0.5 (3.1) 0.5 (.6) 0.5 (2.3)
Number of swollen joints (IQR) 0.0 (2.0) 0.0 (3.0) 0.0 (3.0) 0.0 (4.4)
Number of tender joints (IQR) 0.0 (3.5) 0.0 (4.0) 0.0 (3.8) 0.0 (4.1)
Number of limited joints (IQR) 1.5 (4.0) 2.0 (5.0) 2.5 (5.0) 2.0 (4.0)
All variables are expressed as median values unless otherwise stated.
** p < 0.01 significant difference compared to healthy age and sex related individuals.
van Pelt et al. Pediatric Rheumatology 2012, 10:27 Page 3 of 8
http://www.ped-rheum.com/content/10/1/27VO2peak - predicted VO2peak) / SD] where predicted
VO2peak values were obtained from a database of estab-
lished values for age- and gender- related Dutch controls
[37]. A z-score of zero represents a VO2 similar to that of
healthy controls, while a score of ±1.5 is a clinical import-
ant difference from healthy controls.The JADAS 27 may present an advantage over the DASDisease activity
A number of indicators were used to assess disease activity
including the total number of swollen joints, number of
painful joints, the number of joints with limited range of
motion, number of active joints (defined as joints with
swelling and/ or pain during motion), the Juvenile
Arthritis Disease Activity Score (JADAS 27) [38] and the
Disease Activity Index 28 (DAS28)[39]. All of the exami-
nations were performed by an experienced (paediatric)
rheumatologist. Furthermore, a global assessment was per-
formed by the patient (well being; VAS patient 0-100 mm)as well by a paediatric rheumatologist (disease activity;
PGA 0-100 mm). Given that patients were recruited from
both the paediatric and adult clinics, disease activity scores
commonly used in both the paediatric and adult depart-
ments were computed. In adult Rheumatoid Arthritis
(RA) patients, the DAS28 is a commonly used and
validated tool to measure disease activity [39]. This is a
compound score of the number of a total of swollen joints
(out of 28), the number of a total of painful joints (out of
28), assessment of patient’s general health and the erythro-
cyte sedimentation rate (ESR). Three compound disease
activity scores were recently introduced in paediatric
rheumatology: Juvenile Arthritis Disease Activity Score
(JADAS) 10, JADAS 27 and JADAS 71[38]. We utilised
the JADAS 27 compound score because of its feasibility.
Moreover, statistical performance of JADAS 27 is compar-
able to JADAS 71, while the construct validity of JADAS
10 is poor compared to JADAS 71 and JADAS 27 [38].
Figure 1 Aerobic capacity (expressed as median Z-score of
VO2peak and VO2peak/kg) in relation to age in adolescents and
young adults with JIA. Z scores are compared to age and sex
related healthy controls (p-values <0.01). Abbreviations: Z-score:
standard deviation of the individual patient compared with values
from age- and sex- related historical Dutch controls(37); VO2peak abs:
highest oxygen uptake in liters of oxygen per minute (l/min) during
maximum exercise test in l/min; VO2peak/kgl : highest oxygen uptake
in milliliters of oxygen per kilogram of bodyweight per minute (ml/
min/kg) during maximum exercise.
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and ankles, joints which are often affected in (adult)
patients with JIA.
Medication use
Past and current medication utilization was obtained
from a review of the patient’s medical chart.
Statistical analysis
All statistical analyses were performed using Statistical
Package for Social Science (SPSS) version 15.0 for win-
dows (SPSS Inc., Chicago, IL) version 15.0 for Windows.
Because patient data were non normally distributed non-
parametric tests were used to analyse the demographic
variables and compare the results of the cardiopulmonary
exercise tests (Mann–Whitney and Kruskal-Wallis where
appropriate). Spearman’s Correlation test was used for de-
termining the correlations between VO2peak and disease
activity markers and standard laboratory values. The level
of statistical significance was set at P < 0.05.
Results
Demographics
Demographic and disease related characteristics are pre-
sented in Table 1. In total, 22 boys and 41 girls partici-
pated in the study. The longest disease durations were
seen in the oldest age group. No significant differences
were noted between age groups with respect to disease
duration, body mass index (BMI), disease activity mar-
kers as measured by number of swollen and tender
joints, DAS28, JADAS 27 and laboratory values.
Aerobic capacity
The median peak heart rate was 187 beats per minute
(Interquartile range [IQR] 17), indicating an adequate
level of maximum achieved exercise. The median aer-
obic capacity in all patients with JIA was considerably
lower compared to healthy peers, with a median z-
score of −0.8 (p < 0.01) for absolute VO2peak (L/min)
and −1.5 (p < 0.01) for relative VO2peak/kg (ml/kg/
min) in all patients. VO2peak did not differ signifi-
cantly by gender, disease duration or JIA sub-type;
therefore all patients were merged for further analysis.
There were no statistical significant differences in the
z-scores for absolute and relative VO2peak between the
different age groups (Figure 1).
Aerobic capacity and disease activity
Spearman’s correlation coefficient revealed a signifi-
cant negative correlation between the number of
swollen joints and absolute VO2peak z-score, but not
with relative VO2peak z-score (Table 2). No significant
correlations were seen between VO2peak values and
the number of painful joints. Both disease severitycompound scores (DAS28 and JADAS 27) showed
significant moderately strong negative associations
with all VO2peak values (Table 2).
A substantial proportion of the patients presented
with low disease activity as reflected by low median
numbers of swollen and painful joints (Table 2). The
patients were divided into 2 groups based on disease
activity status, these included patients in remission or
inactive disease (defined by Wallace et al. [40], active
joint count zero; DAS28 ≤2.6) and a patient group
with disease activity (active joint count one and
higher; DAS28 > 2.6) [40,41]. Between these patient
groups, significant differences as measured by active
joint count and DAS28 score were seen (figure 2).
Significant negative correlations were observed be-
tween laboratory parameters reflecting disease activity
(ESR, thrombocytes) and the aerobic capacity
(Table 3). Conversely, no relationship was seen be-
tween C-reactive protein, an acute phase protein and
VO2peak (Table 3). We found a positive significant
correlation between serum haemoglobin and the rela-
tive VO2peak/kg in boys as well in the total patient
group. In girls, a positive significant correlation be-
tween serum haemoglobin and the absolute VO2peak
Table 2 Median values (IQR) of Disease activity markers and Spearman’s Correlation Coefficient values for Aerobic
Capacity, expressed by absolute and relative VO2 peak
Median
(IQR)
Correlation Correlation
Z-score VO2peak Z–score VO2peak/kg
(p -value) (p -value)
Number of swollen joints in lower extremities 0.0 (0) −0.3 (**) −0.1
number of swollen joints in upper and lower extremities 0.0 (2) −0.3 (**) −0.1
Number of painful joints lower extremities 0.0 (2) −0.1 −0.1
number of painful joints in upper and lower extremities 0.0 (4.0) −0.2 −0.1
number of limited joints in upper and lower extremities 2.0 (4.0)) −0.3 (*) −0.3 (*)
Active joint count 0.0 (0) −0.3 (**) −0.2
VAS patient 0.5 (2.6) −0.3 (*) −0.3 (*)
DAS28 1.6 (1.2) −0.4 (**) −0.4 (**)
JADAS 27 2.9 (9.0) −0.3(**) −0.4(**)
level of significance:* indicates significance < 0.05; ** indicates significance <0.01.
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VO2peak/kg values were noted in patients with an-
aemia compared to those who were not anaemic
(p < 0.05).Figure 2 Aerobic capacity (expressed as Z-score of VO2peak and
VO2peak/kg) in relation to disease activity in adolescents and
young adults with JIA in remission and with active disease.
Z scores are compared to age and sex matched healthy controls
(* p-values <0.05; **p-values <0.01). Abbreviations: Z-score: standard
deviation of the individual patient compared with values from
age- and sex- related historical Dutch controls(37); VO2peak abs:
highest oxygen uptake in liters of oxygen per minute (l/min) during
maximum exercise test in l/min; VO2peak/kgl : highest oxygen uptake
in milliliters of oxygen per kilogram of bodyweight per minute
(ml/min/kg) during maximum exercise; AJC: Active Joint Count;
DAS28: Disease Activity Score of 28 joints.Aerobic Capacity and Use of Disease Modifying Anti-
Rheumatic Drugs (DMARD)
Thirteen of our patients were not using any DMARD at
the time of the testing, 38 patients were using one
DMARD, 11 patients were using a combination of two
DMARD’s and only 1 patient was on a combination
therapy of three DMARD’s. Non-parametric tests
revealed no significant differences in aerobic capacity be-
tween these patients. No significant correlations were
found between current use of DMARD and absolute and
relative VO2peak values. When looking at historical
DMARD use, only use of anti-Tumor Necrosing Factor
biologicals in 10 patients was significantly associated
with lower absolute and relative VO2peak values
(p < 0.05). Duration of current and formerly MTX use
did not affect aerobic capacity.
A total of 6 patients were currently using corticoster-
oids at the time of testing, while 10 patients had used
them the past and 47 patients never used corticoster-
oids. Neither current nor former corticosteroid use was
significantly related to aerobic capacity.
Discussion
Although a favorable long-term outcome is seen in
about half of the patients with JIA [1], results of the
current study highlight a significant impairment in aer-
obic capacity, with a median z score of −1.5 in all
patients (children, adolescents and young adults with
JIA. Although disease duration and DMARD use were
expected to have a negative influence on aerobic cap-
acity, no significant correlations, with the exception of
past biological use were seen between these variables.
Despite the overall low median disease activity in our
patient group, representing the general favorable disease
outcome, aerobic capacity was still significantly reduced
in patients with JIA compared to healthy controls.
Table 3 Median (IQR) Standard Laboratory Values and Spearman’s Correlation Coefficients for Aerobic Capacity
(expressed by absolute and relative VO2 peak) (level of significance:* indicates significance <0.05; ** indicates
significance <0.01)
Median
(IQR)
Correlation with Correlation
Z-score VO2peak (p -value) Z-score VO2peak/kg (p -value)
ESR (mm) 8.0 (13) −0.3 (*) −0.5 (**)
CRP (mg/l) 5.5 (6) −0.2 −0.2
Thrombocytes (10.9/l) 302 (110) −0.4 (**) −0.5(**)
Haemoglobin (mmol/l) boys 8.1 (1.2) +0.0 +0.5 (*)
Haemoglobin (mmol/l) girls 7.8 (1.1) +0.3 (*) +0.2
Legend: Haemoglobin boys (ref: age group 10-12 yrs: 6.6-.8.4 millimol per liter age 12–18 yrs 6.9-9.1 millimol per liter; age >18 yrs: 8.6-10.5 millimol per liter);
Hemoglobin girls (ref: age 10–12 yrs 6.6-8.4 millimol per liter ; age 12–18 yrs 6.8-8.3 millimol per liter ; age >18 yrs:7.5-9.5 millimol per liter).
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ously been reported in youth with other chronic diseases
including Crohn’ disease and dermatomyositis [42-44].
A significant correlation of disease activity with aerobic
capacity was found (Table 2), the strongest correlations
were seen for the compound scores DAS28 and
JADAS27. When considering separate items, aerobic
capacity was significantly related to the number of swol-
len, limited, and active joints, but not to the number of
painful joints. Apparently, joint-pain is a negligible limit-
ing factor in reaching a maximum of exercise levels.
When the study population was divided by disease ac-
tivity status, (remission or inactive disease [40] versus
active disease) significant differences in aerobic capacity
were observed (Figure 2). Since a lower aerobic capacity
was also noted in patients in remission compared with
healthy controls, one might hypothesize that current
indicators of disease activity in JIA are not always suffi-
cient to predict impaired aerobic capacity. As low aer-
obic capacity is linked with an increased risk of
developing other chronic diseases including cardiovascu-
lar diseases, diabetes, cancer, hypertension, obesity, de-
pression and osteoporosis [13], as well as an increased
risk of mortality in adults [14], this current finding is of
importance for the quality of life of all patients with JIA.
Significantly negative correlations were observed be-
tween ESR, thrombocytes and both absolute and relative
aerobic capacity, suggesting that disease activity and sys-
temic inflammation may negatively affect aerobic
capacity. Extensive studies on the role of inflammatory
cytokines (e.g. TNF-α) in maintaining the balance be-
tween muscle protein synthesis and degradation [7] have
lead to the concept of rheumatoid cachexia, a condition
in which muscle protein degradation is favored over syn-
thesis resulting in muscle wasting, impaired muscle
strength and a concomitant increase of fat mass. Body
mass index was used as an indirect parameter of body
composition in the current study, but did not reveal any
significant relationship with aerobic capacity. Although
it has been described a common complication in JIA[45], we did not find a significant growth retardation
(median length 50th percentile; median weight 49th
percentile) in our population.
Future studies in patients with JIA might also consider
the inclusion of detailed determination of body compos-
ition (muscle mass, fat mass and bone mass) next to
muscle strength testing.
This is the first study in patients with JIA to show
lower aerobic capacity in individuals with lower serum
hemoglobin .This correlation may be explained by a
lower oxygen transport capacity to the muscles. In
chronic conditions like end-stage kidney disease, anemia
is thought to at least partly explain the observed reduc-
tion in aerobic capacity [46]. Anemia is often considered
a reflection of disease activity [47], suggesting that per-
haps the observed correlation with aerobic capacity is
due to disease activity, rather than anaemia per se; how-
ever, this relationship remained significant when the data
were corrected for disease activity.
In our study, no evidence for the influence of any
DMARD or glucocorticoids intake on aerobic capacity
was found, and also duration of MTX treatment was not
correlated with VO2peak. Although in earlier days MTX
treatment was limited to more severe disease course, in
our study population, MTX is used in all subtypes of JIA
and in almost all patients (61 out of 63 patients). Only
past anti-TNF biological therapy appeared to negatively
influence aerobic capacity; this may be related to the fact
that anti-TNF in the Netherlands is restricted to patients
with a poly-articular disease course after failure of treat-
ment with, or untreatable side effects of high dose MTX.
This suggests that a more severe disease course, rather
than biological therapy, per se, is associated with a lower
aerobic capacity. It is important to note that despite our
finding of similar disease activity among all JIA subtypes
and DMARD utilization, generally patients with a poly-
articular and systemic JIA are considered to have a more
severe disease course.
In long standing JIA muscle atrophy, decreased muscle
strength and lower extremity deformities might serve to
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RA, patients with JIA may have low levels of physical
activity (hypo activity) [22], highlighting the need for
more rigorous training programs in this population to
prevent the increased risk of developing chronic diseases
like cardiovascular disease and diabetes [13,48,49]. In
the present study, approximately 73% of the patients
reported participating in sport more than 12 times a
year, compared with 68% in general population [35]. In
our study, sport participation was not significantly corre-
lated with aerobic capacity (results not shown).
We realize that the current patient group represents a
select group of patients that may not be reflective of the
general pediatric and young adult rheumatology popula-
tion. More specifically, since the patients in our study,
are at least 10 years of age, the percentage of persistent
oligo-articular patients is lower than the proportion typ-
ically seen in the pediatric outpatient clinic. Despite this
patient selection, it is remarkable that a negative correl-
ation was observed between disease activity and aerobic
capacity, which persisted into adulthood. Furthermore it
is also important to note that although a number of cor-
relations presented were only moderately strong, they
remained significant and were consistent across several
markers that reflect disease activity, namely DAS 28,
JADAS 27, and laboratory markers like ESR, thrombo-
cytes and hemoglobin.
Conclusions
Our results demonstrate that children, adolescents and
young adults with JIA suffer from reduced aerobic cap-
acity. This impairment in aerobic capacity was seen in
patients with active disease as well as those in remission.
Further, we report that aerobic capacity is negatively cor-
related to disease activity, as measured by physical
examination as well as several laboratory parameters.
Given that poor aerobic capacity has been linked with a
number of healthy complications, these findings high-
light the need for longstanding follow up into adulthood
of patients with JIA, even if disease activity is low or in
remission.
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